ACADIA Pharma (ACAD): Pangali EV/EBITDA

ACADIA Pharmaceuticals dominates the rare brain pathology niche thanks to patents on unique molecules. The EV/EBITDA valuation multiple reflects market expectations, where 14.26 is established as the baseline value. Growth is driven by therapies for Parkinson's disease psychosis and Rett syndrome. Stability is underpinned by a secure cash flow, despite the reliance on key drugs.

For long-term asset screening, analyzing business value relative to operational efficiency is critical. The enterprise value to EBITDA ratio for ACADIA Pharmaceuticals (ACAD), which stands at 14.26, allows for a valuation that accounts for debt; given stable patent protection in the US, this minimizes risks and reflects the real-time dynamics in the history of the EV/EBITDA multiple.